Wolfgang Dummer - 26 Jan 2023 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Reporting relationship: EVP & CMO
Issuer ticker: RIGL
Reported as of: 26 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jan 2023, 20:45:49 UTC
Prior SEC filing: 30 Dec 2022
Next SEC filing: 06 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Raymond Furey (Attorney-in-Fact)

Key filing fact

Wolfgang Dummer filed Form 4 for RIGEL PHARMACEUTICALS INC (RIGL) on 30 Jan 2023.

Key facts

This page summarizes Wolfgang Dummer's Form 4 filing for RIGEL PHARMACEUTICALS INC (RIGL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Jan 2023, 20:45.

Change

Previous filing in this sequence was filed on 30 Dec 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RIGL transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +50,000
Change %: +100%
Price: $0.000000
Shares after: 100,000
Date: 26 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $2.42
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person was granted an option with a performance-based condition with respect to 50,000 shares of common stock on January 24, 2022. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On January 26, 2023, it was determined that the performance metric had been met.

Footnote F2

The option was fully vested on January 26, 2023, the date the determination was made that the performance metric had been met.